US 12,338,466 B2
Therapeutic nuclease compositions and methods
Jeffrey A. Ledbetter, Seattle, WA (US); Martha Hayden-Ledbetter, Seattle, WA (US); Keith Elkon, Seattle, WA (US); and Xizhang Sun, Seattle, WA (US)
Assigned to University of Washington, Seattle, WA (US)
Filed by University of Washington, Seattle, WA (US)
Filed on May 19, 2021, as Appl. No. 17/324,641.
Application 17/324,641 is a continuation of application No. 16/229,431, filed on Dec. 21, 2018, granted, now 11,034,944.
Application 16/229,431 is a continuation of application No. 13/822,215, granted, now 10,202,588, issued on Feb. 12, 2019, previously published as PCT/US2012/035614, filed on Apr. 27, 2012.
Claims priority of provisional application 61/617,241, filed on Mar. 29, 2012.
Claims priority of provisional application 61/480,961, filed on Apr. 29, 2011.
Prior Publication US 2021/0395711 A1, Dec. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 47/68 (2017.01); C07K 16/44 (2006.01); C12N 9/22 (2006.01); A61K 38/46 (2006.01); C07K 1/00 (2006.01)
CPC C12N 9/22 (2013.01) [A61K 47/68 (2017.08); A61K 47/6815 (2017.08); C07K 16/44 (2013.01); A61K 38/465 (2013.01); C07K 2319/30 (2013.01); C12Y 301/27005 (2013.01)] 30 Claims
 
1. A method for reducing or inhibiting interferon (IFN) production in a subject comprising administering to the subject a composition comprising: a polypeptide consisting of human RNase 1 operatively coupled with or without a linker to a mutant human IgG1 Fc domain, wherein the Fc domain comprises a P238S mutation and a P331S mutation, numbering according to the EU index, and wherein the Fc domain does not contain a variable region that binds antigen; and a pharmaceutically acceptable carrier.